Walleye Diversifies Investments
Walleye Capital Establishes New Stakes and Expands Holdings in Five Biotech and Industrial Firms
Key Points
TYRA had notable market data and analyst coverage in Q2: shares opened at $25.29, the stock carries roughly a $1.51B market cap with a negative trailing P/E (-10.54) and a beta of 0.77, and JonesTrading began coverage with a Buy rating.
CAI saw significant external ownership activity: Renaissance Technologies increased its stake to 449,900 shares, UBS Group AG rose to 2,183,980 shares, and Sei Investments held about 598,712 shares.
ZBIO's ownership landscape includes major ongoing positions by Federated Hermes (2,715,578 shares, about $98.6M), NEA Management (3,523,219 shares, about $127.9M), and Bank of America (388,347 shares, about $7.6M), with Polar Capital also taking a new stake.
GATX CFO transition activity: CFO Thomas A. Ellman sold 18,200 shares on Aug. 5 at an average price of $180.08, reducing direct ownership to 34,361 shares (about $6.19M) and lowering ownership by about 34.6%.
RAL touched dividend news alongside the new stake: the company declared a quarterly dividend of $0.05 per share, payable Sept. 23, with an ex-dividend date of Sept. 8 and a yield around 0.3% (annualized $0.20).
Hedge fund Walleye Capital LLC quietly built a $11.11 million stake in biotech firm Tyra Biosciences (TYRA) during the second quarter, snapping up 347,898 shares, according to Watchlist News. The move is one of several new positions the firm opened across biotech and industrial stocks between April and June.
Beyond Tyra, Walleye also entered Caris Life Sciences (CAI) with 424,407 shares worth $7.56 million, took 209,050 shares of Zenas BioPharma (ZBIO) for $5.31 million, and built positions in GATX Corporation and Ralliant Corporation worth $21.69 million and $10.52 million respectively.
Tyra Biosciences Draws New Institutional Money in Q2
Tyra Biosciences carries a market cap of roughly $1.51 billion, according to Watchlist News. The stock opened Q2 at $25.29 per share. Its trailing price-to-earnings ratio sits at -10.54, meaning the company is not yet profitable. Its beta of 0.77 signals it moves less sharply than the broader market.
Analyst firm JonesTrading started coverage of TYRA with a Buy rating during the quarter. That vote of confidence may have drawn fresh institutional interest. Walleye's $11.11 million bet is one of the larger new positions reported so far for the period.
Caris and Zenas See Crowded Institutional Buying
Walleye was not alone in circling Caris Life Sciences. Renaissance Technologies raised its stake to 449,900 shares. UBS Group AG climbed to 2,183,980 shares. Sei Investments held about 598,712 shares, per Watchlist News. That kind of broad institutional buying often signals confidence in a company's near-term prospects.
Zenas BioPharma (ZBIO) drew similarly heavy ownership. Federated Hermes held 2,715,578 shares worth about $98.6 million. NEA Management sat at 3,523,219 shares valued near $127.9 million. Bank of America owned 388,347 shares worth $7.6 million. Polar Capital also opened a new stake alongside Walleye during the quarter.
GATX CFO Sells Big Stake Amid Walleye's Purchase
Walleye added 122,415 GATX shares worth $21.69 million — its largest new position by dollar value. But insiders were moving in the opposite direction. CFO Thomas A. Ellman sold 18,200 shares on August 5 at an average price of $180.08 per share, according to Watchlist News.
After the sale, Ellman held 34,361 shares worth about $6.19 million. That sale cut his direct ownership by roughly 34.6%. Insider selling does not always mean trouble, but the size of the reduction is worth watching alongside new institutional buying.
Ralliant Declares Dividend as Walleye Opens Position
Walleye picked up 142,904 shares of Ralliant Corporation (RAL) for about $10.52 million. The timing lines up with fresh dividend news from the company. Ralliant declared a quarterly dividend of $0.05 per share, per Watchlist News. The payment is due September 23, with an ex-dividend date of September 8.
The annualized dividend works out to $0.20 per share, giving the stock a yield of about 0.3%. That is a modest payout, but dividend announcements often attract income-focused investors. Walleye's entry ahead of the ex-dividend date puts the fund in line to collect the upcoming payment.
Sentiment
Mostly PositivePublishers
27
Articles
23
Reach
50
